Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:NUVLNASDAQ:PTCTNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.44-3.2%$5.40$4.32▼$9.33$1.30B0.874.39 million shs3.27 million shsNUVLNuvalent$72.52+3.2%$78.83$61.80▼$113.51$5.19B1.42459,747 shs613,772 shsPTCTPTC Therapeutics$53.61+1.9%$48.31$24.00▼$55.60$4.23B0.66741,772 shs837,353 shsVRNAVerona Pharma$67.60+7.8%$58.14$11.39▼$70.40$5.46B0.391.55 million shs1.84 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+7.25%+3.88%+0.72%+5.64%-33.80%NUVLNuvalent+4.26%-1.90%-18.01%-24.95%-16.01%PTCTPTC Therapeutics+0.19%+1.53%+6.31%+5.88%+71.30%VRNAVerona Pharma+2.20%-7.11%+4.05%+56.91%+294.09%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.4955 of 5 stars4.51.00.04.43.12.50.6NUVLNuvalent1.7865 of 5 stars3.40.00.00.02.43.30.0PTCTPTC Therapeutics3.203 of 5 stars3.31.00.04.42.10.80.0VRNAVerona Pharma1.4066 of 5 stars2.61.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.95101.29% UpsideNUVLNuvalent 2.85Moderate Buy$113.1055.96% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$63.5418.52% UpsideVRNAVerona Pharma 3.14Buy$69.142.28% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, VRNA, NUVL, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/7/2025ARDXArdelyxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/7/2025ARDXArdelyxLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$11.003/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.003/4/2025ARDXArdelyxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/4/2025ARDXArdelyxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.003/3/2025NUVLNuvalentHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.002/28/2025VRNAVerona PharmaRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$83.002/28/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $72.002/28/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $93.00(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.62M3.89N/AN/A$0.73 per share7.45NUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/APTCTPTC Therapeutics$806.78M5.24$2.58 per share20.80($10.85) per share-4.94VRNAVerona Pharma$42.28M129.22N/AN/A$3.10 per share21.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.16N/A17.55N/A-11.73%-24.87%-10.51%5/1/2025 (Estimated)NUVLNuvalent-$126.22M-$3.90N/AN/AN/AN/A-28.63%-27.15%5/8/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)VRNAVerona Pharma-$54.37M-$2.16N/A2,253.33N/AN/A-79.54%-43.49%5/8/2025 (Estimated)Latest ARDX, VRNA, NUVL, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2025Q4 2024NUVLNuvalent-$1.03-$1.05-$0.02-$1.05N/AN/A2/20/2025Q4 2024ARDXArdelyx$0.02$0.02N/A$0.02$111.16 million$116.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31NUVLNuvalentN/A23.0723.07PTCTPTC TherapeuticsN/A2.102.04VRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%NUVLNuvalent97.26%PTCTPTC TherapeuticsN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.90%NUVLNuvalent12.52%PTCTPTC Therapeutics5.50%VRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90238.36 million222.88 millionOptionableNUVLNuvalent4071.60 million62.16 millionOptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableVRNAVerona Pharma3080.82 million76.10 millionOptionableARDX, VRNA, NUVL, and PTCT HeadlinesRecent News About These CompaniesPersonal CFO Solutions LLC Makes New $284,000 Investment in Verona Pharma plc (NASDAQ:VRNA)March 11 at 4:29 AM | marketbeat.comKeybank National Association OH Acquires Shares of 6,460 Verona Pharma plc (NASDAQ:VRNA)March 11 at 3:36 AM | marketbeat.comVerona Pharma management to meet with TruistMarch 7, 2025 | markets.businessinsider.comCandriam S.C.A. Lowers Stake in Verona Pharma plc (NASDAQ:VRNA)March 7, 2025 | marketbeat.comNew York State Common Retirement Fund Makes New $285,000 Investment in Verona Pharma plc (NASDAQ:VRNA)March 6, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for Verona Pharma (VRNA)March 5, 2025 | markets.businessinsider.comVerona Pharma plc (VRNA): A Bull Case TheoryMarch 5, 2025 | insidermonkey.comBrokerages Set Verona Pharma plc (NASDAQ:VRNA) PT at $66.83March 5, 2025 | americanbankingnews.comBeat the Market the Zacks Way: Verona, Visa, Starbucks in FocusMarch 3, 2025 | finance.yahoo.comVerona Pharma management to meet with Piper SandlerMarch 3, 2025 | markets.businessinsider.comHC Wainwright Comments on Verona Pharma Q1 EarningsMarch 3, 2025 | americanbankingnews.comHC Wainwright Predicts Verona Pharma Q1 EarningsMarch 3, 2025 | marketbeat.comEarnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 2, 2025 | finance.yahoo.comHC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockMarch 2, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) Given Average Rating of "Buy" by AnalystsMarch 2, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High Following Analyst UpgradeMarch 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $93.00March 1, 2025 | marketbeat.comVerona Pharma price target raised to $75 from $60 at H.C. WainwrightMarch 1, 2025 | markets.businessinsider.comVerona Pharma price target raised to $76 from $57 at TruistMarch 1, 2025 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Stock Price Expected to Rise, HC Wainwright Analyst SaysMarch 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPSFebruary 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, VRNA, NUVL, and PTCT Company DescriptionsArdelyx NASDAQ:ARDX$5.44 -0.18 (-3.20%) Closing price 04:00 PM EasternExtended Trading$5.46 +0.02 (+0.37%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Nuvalent NASDAQ:NUVL$72.52 +2.27 (+3.23%) Closing price 04:00 PM EasternExtended Trading$72.60 +0.09 (+0.12%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.PTC Therapeutics NASDAQ:PTCT$53.61 +1.02 (+1.94%) Closing price 04:00 PM EasternExtended Trading$53.58 -0.02 (-0.05%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Verona Pharma NASDAQ:VRNA$67.60 +4.90 (+7.81%) Closing price 04:00 PM EasternExtended Trading$67.88 +0.28 (+0.41%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
